1 week Eli Lilly Jumps, Reversing Its Weight-Loss Setback, On A Strong 2025 Outlook Investor's Business Daily X
2 weeks The Zacks Analyst Blog Highlights Merck, Pfizer, Eli Lilly, Amgen and Bristol Myers Squibb Zacks X
2 weeks Eli Lilly CEO Hasn’t Bought Company Shares in Years. He Just Bought This Stock. Yahoo Finance X
3 weeks Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It. Yahoo Finance X
3 weeks Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho’s Jared Holz YouTube X
3 weeks Allurion Catapults 132% On Its Plans To Outdo Eli Lilly, Novo Nordisk Investor's Business Daily X
4 weeks Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity? Yahoo Finance X
1 month After Eli Lilly’s 7% Slump On Its Guidance Cut, What’s Left To Like? A Lot, Says One Analyst. Investor's Business Daily X
1 month Eli Lilly Stumbled But Weight-Loss Drugs Will Continue to Fuel Markets. Here’s Why and 5 Other Things to Know Today. Yahoo Finance X
1 month Eli Lilly and Company (LLY) CEO Dave Ricks presents at 43rd Annual J.P. Morgan Healthcare Conference (Transcript) Seeking Alpha X
1 month Eli Lilly stock tumbles after new forecasts show weight-loss drug sales grow slower than expected Yahoo Finance X
Stock Market News